Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. - Wikidata - awgldk - TriplyDB

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

http://www.wikidata.org/entity/Q41968982

about

GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe.Whole-genome sequencing to control antimicrobial resistance Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis.Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012 Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study.Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance Performance of a pyrosequencing platform in diagnosing drug-resistant extra-pulmonary tuberculosis in India Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013.A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays.Current tools available for the diagnosis of drug-resistant tuberculosis.Resistance to rifampicin: a review.Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Mycobacterium tuberculosis resistance prediction and lineage classification from genome sequencing: comparison of automated analysis tools.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.Mutations Found in embCAB, embR, and ubiA Genes of Ethambutol-Sensitive and -Resistant Mycobacterium tuberculosis Clinical Isolates from China.Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus.Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania.Pathogen-based precision medicine for drug-resistant tuberculosis

P2860

Q28068545-B772FAA0-80E3-41DD-8F2F-6E4BA609E70E Q28397752-31BBA1C5-E80C-4F90-9CC4-6A0217A58961 Q28484917-ECE66580-1396-4F12-A7D7-C1CCB6143014 Q28488204-DAD53F1E-06EF-4009-80F2-6955FB832493 Q33576909-9726C9CC-A1A3-446F-9A63-BC797725DBEA Q33745972-41B24CA9-A05D-4EFB-9EE4-7A7B7739BB86 Q34142073-14FAB2AD-A999-43C0-8F11-524F95DE3324 Q34604407-6752C8BC-F720-4BA0-961A-E35727B76660 Q34922635-7CC8BB43-C9EB-43F1-8DAA-34B7FD9D8335 Q34922710-5E3269F2-07A0-4074-A5CF-75BE5780C207 Q35105829-359BB722-2980-4626-814F-352BDF859EF0 Q35644365-562B1343-9A92-4CD3-96DF-27F7B5737942 Q36084640-A8A12501-40D7-47B4-B4AB-C937661ACE2A Q36396241-B410F567-00DE-4F08-A150-2D701DFB20FA Q36495442-69C1376F-D3F5-4DBF-856B-1024AEA9710D Q36844683-D65518EC-230C-4241-AC68-6A4A54596870 Q37203747-3BF1A62B-FD1C-414A-AA9F-1F6DA9BACBF9 Q37305611-FCDBE24D-7FFF-414C-B9CB-E1D2F85D9DDF Q37434301-F32FEE83-8FA2-4F12-9B30-5896A1314FFB Q37544293-0AD099E8-08C7-4C77-849E-991D6DAF503B Q37720805-22D8D977-0C27-4FD2-9E3C-34CDF3E2FF67 Q37732222-ADD2F660-72FF-4A7F-BDB4-D14600C6E3E1 Q38239459-91B4AE52-91E8-4034-ADED-2370AD0074D3 Q38368943-A9B738E5-A581-4543-A04C-58629130FAA9 Q38763608-A9898FF6-71BD-4987-92DD-58A5AB083E0F Q38829192-64694C20-4A39-4F0E-A9C6-D7F13A349001 Q38845761-41CE7ADC-7A58-4D77-AB5B-D363F62D7500 Q40043590-0C9B9B28-BA5E-4E35-9809-D9FEFB1A4655 Q40487996-80094B0D-AD4E-4D0A-9D92-47D72516C63C Q40922172-42B871EB-B365-4E2B-8D2A-ADEF7DB5E781 Q41105755-4EB7416F-36D7-4878-AEA7-D788C0F36AF4 Q41991754-77161F8A-84D9-4DAD-8C38-26298B0AFAE9 Q42430318-4789B19D-D55B-49E5-A5A3-4767D26D0298 Q46319545-B0212929-7826-47EF-98C0-7E7273A60CE3 Q47897771-F780E2F0-ED9A-467F-A550-646D0533FAA3 Q50033600-EB3FF084-D5B4-4168-8ACC-75B10810B8C7 Q53698791-9EDCEAD4-11A1-403E-8BE0-DF102D0E9F95 Q55424405-1DDCD10D-E26E-445A-9AD1-17AE08E8807D Q58602447-EA52FBD2-7C5E-4D88-B5A6-4788C8832B43

P2860

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

http://www.wikidata.org/entity/Q41968982

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Challenging a dogma: antimicro ...... or Mycobacterium tuberculosis.

@en

type

label

Challenging a dogma: antimicro ...... or Mycobacterium tuberculosis.

@en

prefLabel

Challenging a dogma: antimicro ...... or Mycobacterium tuberculosis.

@en

P1433

Q41968982-2334F517-2368-487C-94A4-90A4F9E47FFD

P1476

Q41968982-46BC7A3A-06AC-4DAD-86E1-014FD3988E3D

P2093

Q41968982-49FF4698-B665-49BE-9F29-254AC734F5F7

Q41968982-4A924CCD-1DD3-4DAF-AB6D-2D4869A6F579

Q41968982-5C3595F9-9F2D-46C6-8BC2-20C9A4134BF7

Q41968982-5FBD2A90-E0A6-4908-917E-E7DB4357EA63

Q41968982-BF6A9125-A7D3-4538-AFBF-83957484FA86

P2860

Q41968982-4E82BFCF-A7C7-465F-B437-943DF8A1F7A3

Q41968982-55623A7C-8FD7-4746-B3E0-10DC9ACE59B7

Q41968982-687413E2-1A0A-49A2-8355-940FCD03B2DB

Q41968982-A1C75303-39E9-4A5D-965B-0A0E142867DA

Q41968982-B83EEB5A-3F0F-4EE4-A73A-20F62D7372F7

Q41968982-D87A5CC2-241A-485D-A918-07BC9D1EF6C0

Q41968982-E72BCC9C-751F-4400-911B-4BF6E5B479F9

Q41968982-E9419EAB-E73C-4AFE-87DB-28C219F82C91

P304

Q41968982-6240ADB2-3443-45E2-9172-BE896CDCF692

P31

Q41968982-5D39C058-E025-47AE-B016-8E71DCA0A596

P356

Q41968982-DC43194E-85EA-4B95-A6F2-AA1C65EB0556

P407

Q41968982-F0C490CE-640B-4C31-9EE1-86B39862E9F8

P433

Q41968982-877E0A12-397C-4BF2-804F-2CEE193B5FB2

P478

Q41968982-6701DFBF-4EBE-4F94-8351-2C7A5823A880

P577

Q41968982-B5F9792D-048D-4ADA-A003-60ACBCFBF48C

P698

Q41968982-23BD2E96-E86F-4BD1-89B6-EA911E0DCE81

P921

Q41968982-7D86FD43-6E98-4C16-B55C-741D57A6489B

P932

Q41968982-99E8EE20-4A2D-4676-B2F3-F3AC7EC80F54

P356

P1433

Bulletin of the World Health Organization

P1476

Challenging a dogma: antimicro ...... or Mycobacterium tuberculosis.

@en

P2093

Gunnar Kahlmeter

http://www.w3.org/2001/XMLSchema#string

Kristian Ängeby

http://www.w3.org/2001/XMLSchema#string

Pontus Juréen

http://www.w3.org/2001/XMLSchema#string

Sven E Hoffner

http://www.w3.org/2001/XMLSchema#string

Thomas Schön

http://www.w3.org/2001/XMLSchema#string

P2860

Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Drug-susceptibility testing in tuberculosis: methods and reliability of results.

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Breakpoints for susceptibility testing should not divide wild-type distributions of important target species.

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.

Antimicrobial susceptibility in Escherichia coli of human and avian origin--a comparison of wild-type distributions.

P304

693-698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2471/BLT.11.096644

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22984314

http://www.w3.org/2001/XMLSchema#string

P921

Mycobacterium tuberculosis

P932

3442398

http://www.w3.org/2001/XMLSchema#string